Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
9.62
+0.61 (6.77%)
Aug 28, 2026, 1:59 PM EDT - Market open

Akari Therapeutics, Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-13.68-12.1-16.65-16.81-23.09-17.21
Net Income
-30.96-17.3-19.79-10.01-17.75-17.42
Earnings Per Share
-23.94-20.55-66.28-81.79-227.41-324.77
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
7.695.22.63.8513.259.36
Total Debt
0.690.753.26---
Net Cash (Debt)
74.45-0.663.8513.259.36
Net Cash Growth
501.46%---70.98%41.54%-33.40%
Net Cash Per Share
5.415.29-2.2131.42169.78174.48

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-10.76-10.57-12.55-16.43-21.5-18.85
Capital Expenditures
------
Free Cash Flow
-10.76-10.57-12.55-16.43-21.5-18.85
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.